A meta-analysis of diabetes mellitus and the risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2056-2062

  Kasper, Jocelyn S ^a   Giovannucci, Edward ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RISK; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; MALE; MODELS, STATISTICAL; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK;

EID: 33845328853     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0410     Document Type: Review

References (62)

1. Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:542-7.
2. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-9.
3. Strickler HD, Wylie-Rosett J, Rohan T, et al. The relation of type 2 diabetes and cancer. Diabetes Technol Ther 2001;3:263-74.
4. La Vecchia C, Negri E, D'Avanzo B, Boyle P, Franceschi S. Medical history and primary liver cancer. Cancer Res 1990;50:6274-7.
5. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004;47:1071-8.
6. Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 2004;90:2171-5.
7. Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005;16:1055-8.
8. Lightfoot N, Conlon M, Kreiger N, et al. Medical history, sexual, and maturational factors and prostate cancer risk. Ann Epidemiol 2004;14:655-62.
9. Rodriguez C, Patel AV, Mondul AM, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161:147-52.
10. Tavani A, Gallus S, Bertuzzi M, et al. Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 2005;47:313-7; discussion 317.
11. Zhu K, Lee IM, Sesso HD, et al. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004;159:978-82.
12. Laukkanen JA, Laaksonen DE, Niskanen L, et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646-50.
13. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41:2887-95.
14. Checkoway H, DiFerdinando G, Hulka BS, Mickey DD. Medical, life-style, and occupational risk factors for prostate cancer. Prostate 1987;10:79-88.
15. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 2005;16:789-97.
16. Glicksman AS, Rawson RW. Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 1956;9:1127-34.
17. Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970;44:673-86.
18. Henderson BE, Bogdanoff E, Gerkins VR, SooHoo J, Arthur M. Evaluation of cancer risk factors in a retirement community. Cancer Res 1974;34:1045-8.
19. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38:435-41.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
23. Coughlin SS, Neaton JD, Sengupta A. Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:1002-6.
24. Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 1985;6:423-36.
25. Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992;136:1110-4.
26. Rosenberg DJ, Neugut AI, Ahsan H, Shea S. Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002;20:157-65.
27. Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
28. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:950-3.
29. Tavani A, Gallus S, Bosetti C, et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002;11:125-8.
30. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3-9.
31. Ragozzino M, Melton LJ III, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:13-9.
32. Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 1995;4:807-11.
33. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002;102:258-61.
34. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5.
35. Thompson MM, Garland C, Barrett-Connor E, et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 1989;129:511-7.
36. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999;10:313-8.
37. Wynder EL, Mabuchi K, Whitmore WF, Jr. Epidemiology of cancer of the prostate. Cancer 1971;28:344-60.
38. Berger AP, Deibl M, Halpern EJ, et al. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia 2005;48:784-9.
39. Peehl DM, Stamey TA. Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol 1986;22:82-90.
40. Polychronakos C, Janthly U, Lehoux JG, Koutsilieris M. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate 1991;19:313-21.
41. Hsing AW, Chua S, Jr., Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001;93:783-9.
42. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 2002;50:1-3.
43. Sandoval DA, Galassetti P, Tate D, Neill A, Davis SN. Leptin responses to antecedent exercise and hypoglycemia in healthy and type 1 diabetes mellitus men and women. J Diabetes Complications 2003;17:301-6.
44. Saglam K, Aydur E, Yilmaz M, Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003;169:1308-11.
45. Suikkari AM, Koivisto VA, Rutanen EM, et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266-72.
46. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Rev 1992;8:229-57.
47. Clauson PG, Brismar K, Hall K, Linnarsson R, Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 1998;58:353-60.
48. Mantzoros CS, Tzonou A, Signorello LB, et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8.
49. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
50. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-52.
51. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
52. LeRoith D, Baserga R, Helman L, Roberts CT, Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
53. Adami H-O, Hunter DJ, Trichopoulos D. Textbook of cancer epidemiology. Monographs in epidemiology and biostatistics; v. 33. Oxford; New York (NY): Oxford University Press; 2002.
54. Jackson FL, Hutson JC. Altered responses to androgen in diabetic male rats. Diabetes 1984;33:819-24.
55. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992;117:807-11.
56. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990;132:895-901.
57. Coffey DS, Isaacs JT. International Union against Cancer. Prostate cancer: a series of workshops on the biology of human cancer: report no. 9. UICC Technical Report Series; v. 48. Geneva: International Union Against Cancer; 1979.
58. Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997;47:273-87.
59. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
60. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53.
61. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977;45:1211-9.
62. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997;6:557-63.